NCT01542463已完成不适用
Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,464
- 主要终点
- HbA1c (glycaemic haemoglobin)
研究概览
简要总结
This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their previous therapy
排除标准
- 未提供
研究组 & 干预措施
IDet users
干预措施: insulin detemir (Drug)
结局指标
主要结局
HbA1c (glycaemic haemoglobin)
Fasting plasma glucose (FBG)
次要结局
- Body weight change
- Adverse drug reactions (ADR)
- Serious adverse drug reactions (SADR)
- Hypoglycaemic episodes
研究者
相似试验
已完成
不适用
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00704574Novo Nordisk A/S159
已完成
不适用
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00735501Novo Nordisk A/S314
已完成
3 期
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00504673Novo Nordisk A/S277
已完成
不适用
Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®DiabetesDiabetes Mellitus, Type 2NCT00658099Novo Nordisk A/S699
已完成
3 期
Efficacy and Safety of Insulin Detemir in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00595374Novo Nordisk A/S114